Merit Cudkowicz, MD, of Harvard Medical School, discusses the results of a phase 2 study—a reduction in functional decline and a significant drop in the death rate in those on the highest dose of the drug, dexpramipexole. See the Dec. 15 issue of Neurology Today for the full-text article: http://bit.ly/uqFbG7.